Pertussis bacteria n↔♥↔$ucleic acid detection kit±↑ (PCR-fluorescent probe method)
Clinical background
Pertussis is a bacterial respi×≤©ratory infection caused by BorΩdetella pertussis infection. People of a€δ≈∑ll ages are susceptible to it, but infants and•₩♠ children are more serio姧"usly ill than adults after infδ£₹₽ection. According to the World<≈ Health Organization (WHO) statistical report, i♣™n 2013, whooping cough caus€↔ed the death of nearly 63,000 ¶δinfants and children under 5 years of age. In recent years, the in×γfection of whooping cough in China has b♣λeen on the rise, and even broke out in→ some areas. According to the clinical big data¶≥₩ analysis carried out×σ by our company, the high incidence season of wh≥©ooping cough is generally from March to Sept★←₹×ember, and the incidencΩ e rate can reach more than 30%.
Whooping cough reappea∑"↕€rs globally, and small babies are criti<"±σcal, and accurate diagnosis has been put on highe☆r demands in the new e䶣 ra!
Clinical manifestations
Pertussis is clinica ↓lly divided into three st"§ages: the incubation period≠©δ, the spasm period, and the recove®≈ry period; the
epidemic season has paroxysmal ★₩spasm cough or vomiting after cou&¥gh, and the severe cas≤'es have subconjunctival he>morrhage or tongue ulcer$φ∑.
Neonate or infant There are unexplained ♣€ε&episodes of bruising φ or suffocation, which are mostly typical ★≠spasms.
Persistent cough, accompanied by chicken c•§♣ries, and increased l•£÷"ymphocytes in the peripheral bloo✘π↔d.
Complications of B. ±™pertussis infection
Respiratory diseasesφ : bronchial pneumonia; bronchiectπ§σasis; pneumothorax; diaphragmφ↔₽atic hernia, etc.
Central diseases: Pertussis encephalopathy
Others: otitis media; bleeding; hernia etc.....
Features
Based on real-time fluorescent PCR technology, t★♣×he first CFDA registe ÷red product in China.
The reaction system of this kit"¶φ contains a dU-UNG enzy≈πβ↓me anti-pollution system to avoid false positiv< ♣e results; the syste←πm contains internal standar¶®"ds to avoid false negative results.
Using highly conserved regions of the B. pertusσ€sis genome as the target area, speci↔≥♣fic primers and fluo≈∏φrescent probes are designed to pe ↓>♠rform PCR amplification to ensure the accuracy≠>>← of the product.
Carry out big data cl≠♠©®inical verification coveri↕≠¶ng national represent©"ative clinical units, with≈÷ outstanding product performaπ↓☆÷nce.
Product performance
|
Pertussis bacteria n¥≤ucleic acid detectio≈ n kit (PCR-fluorescent probe method)₩≠"$
|
|
Sensitivity
|
1.0x104copies / mL
|
|
Linear range
|
1.0x104copies / mL ~ 1.0x 109copies / mL
|
|
Accuracy
|
The detection result coincid "∞≠ence rate is 100%
|
|
Precision
|
Coefficient of variation ¥ ↓<within and between batchesσ↔€ CV≤5%
|
|
Specificity
|
100% specificity, no cross "§φreaction with Streptococcus pneumoniae, Mycob☆ acterium tuberculosisγ☆, Mycoplasma pneumoniae, Epstein-Barr viru¶s, adenovirus, respiratory syncytial virus, etc.
|
|
Anti-interference
|
Mucin, pus, erythromycin, chl✘£oramphenicol did not interfere w±∏ith the test results
|
Application field
Applicable people: dry cough or paroxysmal spasm, accompanied by±←<> chicken-like roar or voα→✔₩miting after cough without other causes for labor÷βatory diagnosis of B. pertussis
Applicable departments: pediatrics, infections, otolaryngology,♣λσ£ etc.
Product information
Test specimen: pharyngeal swab
Technical principle: PCR-fluorescent probe method
Packaging specifications: 24 tests/ kit, 48 tests/ k"it, 96 tests/ kit
Applicable instruments: two-color fluorescence chan nel PCR instrument, including ABI 7500, ABδ★±I 7300 , Roche480, Rochα$↕♥e96, etc.
